

Table 15

RESEARCH AND DEVELOPMENT EXPENDITURES, 1965-1966^{1/}
(millions of dollars)

	1965 <u>Actual</u>	1966 <u>Budgeted</u>
<u>Company Financed or Conducted R&D</u>		
Company Financed Expenditures for Human Use Drugs:		
(1) Amount spent <u>within</u> firms	\$ 285.8	\$ 322.3
a. In the United States	266.6	296.6
b. In foreign countries	19.2	25.7
(2) Amount spent <u>outside</u> firms by	\$ 42.8	\$ 48.8
a. In the United States	37.5	44.0
b. In foreign countries	5.3	4.8
TOTAL, Human Use R&D	<u>\$ 328.6</u>	<u>\$ 371.1</u>
Company Financed Expenditures for Veterinary Use Drugs:		
(1) Amount spent <u>within</u> firms	\$ 21.9	\$ 26.7
(2) Amount spent <u>outside</u> firms	\$ 0.8	\$ 0.9
TOTAL, Veterinary Use R&D	<u>\$ 22.7</u>	<u>\$ 27.6</u>
Government Grants and Contracts for Company Conducted Drug R&D	<u>\$ 13.7</u>	<u>\$ 14.1</u>
TOTAL R&D EXPENDITURES	<u>\$ 365.0</u>	<u>\$ 412.8</u>

^{1/} The data recorded here represent 77 PMA member firms' R&D costs, accounting for practically all industry-conducted ethical pharmaceutical research. Proprietary drug research is excluded. Such ethical drug research and development work as is conducted by other industrial firms is estimated to be about \$12 million.